CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Position Decreased by Altium Capital Management LLC

Altium Capital Management LLC lessened its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 48.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 467,491 shares of the biotechnology company's stock after selling 447,509 shares during the period. Altium Capital Management LLC owned about 0.60% of CytomX Therapeutics worth $482,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Miller Financial Services LLC bought a new position in CytomX Therapeutics during the 4th quarter worth $26,000. Traphagen Investment Advisors LLC acquired a new position in CytomX Therapeutics during the 4th quarter valued at about $31,000. Prudential Financial Inc. increased its stake in shares of CytomX Therapeutics by 76.2% in the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 27,800 shares during the period. Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $104,000. Finally, FMR LLC boosted its position in shares of CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock worth $335,000 after buying an additional 41,949 shares during the period. 67.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. StockNews.com assumed coverage on CytomX Therapeutics in a report on Tuesday, April 15th. They set a "hold" rating on the stock. HC Wainwright reiterated a "neutral" rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Piper Sandler began coverage on CytomX Therapeutics in a research report on Monday, April 14th. They issued an "overweight" rating and a $2.50 target price for the company. Finally, Wedbush reiterated an "outperform" rating and set a $5.00 price target on shares of CytomX Therapeutics in a research report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $4.77.

CytomX Therapeutics Trading Up 4.2 %

Shares of CytomX Therapeutics stock traded up $0.03 on Friday, reaching $0.66. 575,360 shares of the company were exchanged, compared to its average volume of 2,678,955. CytomX Therapeutics, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $5.85. The firm has a market capitalization of $52.55 million, a price-to-earnings ratio of 3.86 and a beta of 1.34. The stock has a fifty day moving average price of $0.64 and a 200-day moving average price of $0.88.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. On average, equities analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.